Non-antibiotics, efflux pumps and drug resistance of Gram-negative rods

• Autorzy: Laudy A.E.
• Języki publikacji: EN

Abstrakty

EN

Non-antibiotic medicinal products consist of drugs with diverse activity against bacteria. Many non-antibiotics demonstrate direct antibacterial activity against Gram-positive cocci. The activity observed against Gram-negative rods is much lower and non-antibiotics primarily from the following groups: non-steroidal anti-inflammatory drugs, cardiovascular and antidepressant medicinal products demonstrate this activity. It has been shown that the low activity of some non-antibiotics or the absence of activity against Gram-negative rods is related, among other things, to the extrusion of these compounds from bacterial cells by multi-drug resistance efflux pumps. Substrates for the resistance-nodulation-division efflux systems include the following non-antibiotics: salicylate, diclofenac, ibuprofen, mefenamic acid, naproxen, amitriptyline, alendronate sodium, nicergoline, and ticlopidine. In addition, interactions between non-antibiotics and multi-drug resistance efflux pumps have been observed. It has also been revealed that depending on the concentration, salicylate induces expression of multi-drug resistance efflux pumps in Escherichia coli, Salmonella enterica subsp. enterica serotype Typhimurium, and Burkholderia cenocepacia. However, salicylate does not affect the expression of the resistance-nodulation-division efflux systems in Stenotrophomonas maltophilia and Acinetobacter baumannii. Most importantly, there were no effects of medicinal products containing some non-antibiotic active substances, except salicylate, as substrates of multi-drug resistance efflux pumps, on the induction of Gram-negative rod resistance to quinolones.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2018
• Tom: 67
• Numer: 2
• Opis fizyczny: p.129-135,ref.

Twórcy

autor

Laudy A.E.

• Department of Pharmaceutical Microbiology, Medical University of Warsaw, Warsaw, Poland

Bibliografia

• Adabi M., M. Talebi-Taher, L. Arbabi, M. Afshar, S. Fathizadeh, S. Minaeian, N. Moghadam-Maragheh and A. Majidpour. 2015. Spread of efflux pump overexpressing-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa by using an efflux pump inhibitor. Infect. Chemother. 47(2): 98–104.
• Al-Bakri A.G., G. Othman and Y. Bustanji. 2009. The assessment of the antibacterial and antifungal activities of aspirin, EDTA and aspirin-EDTA combination and their effectiveness as antibiofilm agents. J. Appl. Microbiol. 107(1): 280–286.
• Asok Kumar K., K. Mazumdar, N.K. Dutta, P. Karak, S.G. Dastidar and R. Ray. 2004. Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol. Pharm. Bull. 27(7): 1116–1120.
• Axon J.M.C. and E.C. Huskisson 1992. Use of aspirin in inflammatory diseases, pp. 295–320. In: Vane J.R. and R.M. Botting (eds). Aspirin and Other Salicylates. Chapman and Hall, London (United Kingdom).
• Bazyleu A. and A. Kumar. 2014. Incubation temperature, osmolarity, and salicylate affect the expression of resistance-nodulation-division efflux pumps and outer membrane porins in Acinetobacter baumannii ATCC 19606T. FEMS Microbiol. Lett. 357(2): 136–143.
• Bown R.L. 2002. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Int. J. Clin. Pract. 56(2): 132–139.
• Cohen S.P., S.B. Levy, J. Foulds and J.L. Rosner. 1993. Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. J. Bacteriol. 175(24): 7856–7862.
• Dastidar S.G., K. Ganguly, K. Chaudhuri and A.N. Chakrabarty. 2000. The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int. J. Antimicrob. Agents. 14(3): 249–251.
• Dasgupta A., S. Chaki, S. Mukherjee, J. Lourduraja, K. Mazumdar, N.K. Dutta and S.G. Dastidar. 2010. Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine. Eur. J. Clin. Microbiol. Infect. Dis. 29(2): 239–243.
• Domenico P., T. Hopkins and B.A. Cunha. 1990. The effect of sodium salicylate on antibiotic susceptibility and synergy in Klebsiella pneumoniae. J. Antimicrob. Chemother. 26(3): 343–351.
• Dutta N.K., S. Annadurai, K. Mazumdar, S.G. Dastidar, J.E. Kristiansen, J. Molnar, M. Martins and L. Amaral. 2007. Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int. J. Antimicrob. Agents. 30(3): 242–249.
• Farha M.A., A. Leung, E.W. Sewell, M.A. D’Elia, S.E. Allison, L. Ejim, P.M. Pereira, M.G. Pinho, G.D. Wright and E.D. Brown. 2013. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. ACS Chem. Biol. 8(1): 226–233.
• Foulds J., D.M. Murray, T. Chai and J.L. Rosner. 1989. Decreased permeation of cephalosporins through the outer membrane of Escherichia coli grown in salicylates. Antimicrob. Agents Chemother. 33(4): 412–417.
• Frantz B. and E.A. O’Neill. 1995. The effect of sodium salicylate and aspirin on NF-kappa B. Science 270(5244): 2017–2019.
• Grkovic S., M.H. Brown and R.A. Skurray 2002. Regulation ofbacterial drug export systems. Microbiol. Mol. Biol. Rev. 66 (4): 671–701.
• Hartog E., O.Menashe, E. Kler and S. Yaron. 2010. Salicylate reduces the antimicrobial activity of ciprofloxacin against extracellular Salmonella enterica serovar Typhimurium, but not against Salmonella in macrophages. J. Antimicrob. Chemother. 65(5): 888–896.
• Hendricks O., T.S. Butterworth and J.E. Kristiansen. 2003. The in vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureus. Int. J. Antimicrob. Agents. 22(3): 262–264.
• Huang Y.W., R.M. Hu, F.Y. Chu, H.R. Lin and T.C. Yang. 2013. Characterization of a major facilitator superfamily (MFS) tripartite efflux pump EmrCABsm from Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 68(11): 2498–2505.
• Kim H.B., M. Wang, C.H. Park, E.C. Kim, G.A. Jacoby and D.C. Hooper. 2009. oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob. Agents Chemother. 53(8): 3582–3584.
• Kriengkauykiat J., E. Porter, O. Lomovskaya and A. Wong-Beringer. 2005. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49(2): 565–570.
• Kristiansen J.E., O. Hendricks, T. Delvin, T.S. Butterworth,L. Aagaard, J.B. Christensen, V.C. Flores and H. Keyzer. 2007. Reversal of resistance in microorganisms by help of non-antibiotics. J. Antimicrob. Chemother. 59(6): 1271–1279.
• Kristiansen J.E., V.F. Thomsen, A. Martines, M. Viveiros andL. Amaral. 2010. Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo. 24(5): 751–754.
• Kruszewska H., T. Zaręba and S. Tyski. 2002. Search of antimicrobial activity of selected non-antibiotics drugs. Acta Pol. Pharm. Drug Res. 59(6): 436–439.
• Kruszewska H., T. Zaręba and S. Tyski. 2004. Examination of antimicrobial activity of selected non-antibiotics drugs. Acta Pol. Pharm. Drug Res. 61(Suppl. 5): 18–21.
• Kruszewska H., T. Zaręba and S. Tyski. 2008. Examination of antibacterial and antifungal activity of selected non-antibiotic products. Acta Pol. Pharm. Drug Res. 65(6): 779–782.
• Kruszewska H., T. Zaręba and S. Tyski. 2010. Examination of antimicrobial activity of selected non-antibiotic products. Acta Pol. Pharm. Drug Res. 67(6): 733–736.
• Kubo I., K. Fujita, K. Nihei and N. Masuoka. 2003. Non-antibiotic antibacterial activity of dodecyl gallate. Bioorg. Med. Chem. 11(4): 573–580.
• Lomovskaya O., K. Lewis and A. Matin. 1995. EmrR is a negative regulator of the Escherichia coli multidrug resistance pump EmrAB. J. Bacteriol. 177(9): 2328–2334.
• Lomovskaya O., M.S. Warren, A. Lee, J. Galazzo, R. Fronko,M. Lee, J. Blais, D. Cho, S. Ckamberland, T. Renau and others. 2001. Identification and characterization of inhibitors of multi-drug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45(1): 105–116.
• Laudy A.E. 2008. MDR efflux pumps – the mechanism of Gram-negative rods resistance to antibiotics. Post. Mikrobiol. 47(3): 415–422.
• Laudy A.E., E. Kulińska and S. Tyski. 2017. The impact of efflux pump inhibitors on the activity of selected non-antibiotic medicinal products against Gram-negative bacteria. Molecules. 22(1): E114. doi:10.3390/molecules22010114.
• Laudy A.E., A. Mrówka, J. Krajewska and S. Tyski. 2016. The influence of efflux pump inhibitors on the activity of non-antibiotic NSAIDS against Gram-Negative rods. PLoS ONE. 11(1): e0147131. doi:10.1371/journal.pone.0147131.
• Laudy A.E., P. Osińska, A. Namysłowska, O. Zając and S. Tyski. 2015. Modification of the susceptibility of Gram-negative rods producing ESβLs to β-lactams by the efflux phenomenon. PLoS ONE. 10(3): e0119997. doi:10.1371/journal.pone.0119997.
• Li X.Z., P. Plesiat and H. Nikaido. 2015. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28(2): 337–418.
• Martins M., S.G. Dastidar, S. Fanning, J.E. Kristiansen, J. Molnar, J.M. Pages, Z. Schelz, G. Spengler, M. Viveros and L. Amaral. 2008. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int. J. Antimicrob. Agents. 31(3): 198–208.
• Mazumdar K., K. Asok Kumar and N.K. Dutta. 2010. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: Scope and hope for the future. Int. J. Antimicrob. Agents. 36(4): 295–302.
• Mazumdar K., N.K. Dutta, S.G. Dastidar, N. Motohashi andY. Shirataki. 2006. Diclofenac in the management of E. coli urinary tract infections. In Vivo 20(5): 613–620.
• Mazumdar K., N.K. Dutta, K.A. Kumar and S.G. Dastidar. 2005. In vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biol. Pharm. Bull. 28(4): 713–717.
• Miriagou V., G. Cornaglia, M. Edelstein, I. Galani, C.G. Giske, M. Gniadkowski, E. Malamou-Lada, L. Martinez-Martinez, F. Navarro, P. Nordmann and others. 2010. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin. Microbiol. Infect. 16(2): 112–122.
• Nair B.M., K.J. Cheung Jr., A. Griffith and J.L. Burns. 2004. Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J. Clin. Invest. 113(3): 464–473.
• Nikaido H. and J.M. Pages. 2012. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36(2): 340–363.
• Pagès J.M. and L. Amaral. 2009. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta. 1794(5): 826–833.
• Piddock L.J. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19(2): 382–402.
• Poirel L., R.A. Bonnin and P. Nordmann. 2012. Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. Infect. Genet. Evol. 12(5): 883–893.
• Price C.T., I.R. Lee and J.E. Gustafson. 2000. The effects of salicylate on bacteria. Int. J. Biochem. Cell Biol. 32(10): 1029–1043.
• Shirin H., S.F. Moss, S. Kancherla, K. Kancherla, P.R. Holt,I.B. Weinstein and E.M. Sordillo. 2006. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori. J. Gastroenterol. Hepatol. 21(9): 1388–1393.
• Rosner J.L. 1985. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. Proc. Natl. Acad. Sci. USA 82(24): 8771–8774.
• Tanabe H., K. Yamasak, M. Furue, K. Yamamoto, A. Katoh,M. Yamamoto, S. Yoshioka, H. Tagami, H.A. Aiba and R. Utsumi. 1997. Growth phase-dependent transcription of emrKY, a homolog of multidrug efflux emrAB genes of Escherichia coli, is induced by tetracycline. J. Gen. Appl. Microbiol. 43(5): 257–263.
• Tamanai-Shacoori Z., V. Shacoori, A. Jolivet-Gougeon, J.M. Vo Van, M. Repere, P. Donnio and M. Bonnaure-Mallet. 2007. The antibacterial activity of tramadol against bacteria associated with infectious complications after local or regional anesthesia. Anesth. Analg. 105(2): 524–527.
• Wang W.H., W.M. Wong, D. Dailidiene, D.E. Berg, Q. Gu,K.C. Lai, S.K. Lam and B.C. Wong. 2003. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut. 52(4): 490–495.
• WHO (World Health Organization). 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1, 2018.03.24.
• Wu K.K. 2000. Aspirin and salicylate, an old remedy with a new twist. Circulation. 102(17): 2022–2023.
• Yamane K., J. Wachino, S. Suzuki and Y. Arakawa. 2008. Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. Antimicrob. Agents Chemother. 52(4): 1564–1566.
• Yin Z., Y. Wang, L.R. Whittell, S. Jergic, M. Liu, E. Harry,N.E. Dixon, M.J. Kelso, J.L. Beck and A.J. Oakley. 2014. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem. Biol. 21(4): 481–487.

Identyfikatory

DOI

10.21307/pjm-2018-017